Inclusion Criteria:

          -  Signed informed consent form

          -  Age 18-75 years

          -  Newly diagnosed with hepatocellular carcinoma

          -  Have measurable disease

          -  Have disease that responds to DEB-TACE

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Body weight >30 kg

          -  Evidence of clinical or radiographic ascites with a score < 7

          -  Patients must have adequate organ function defined by study-specified laboratory
             tests.

          -  Evidence of post-menopausal status or negative pregnancy test

          -  Willing and able to comply with study procedures

          -  Willing to undergo a liver biopsy

        Exclusion Criteria:

          -  Anyone involved with the planning and/or conduct of the study.

          -  Has participated in another investigational study during the last 6 months.

          -  Any concurrent anticancer therapy or received therapy ≤30 days prior to study.

          -  Major surgical procedure at the time of study enrollment or within 28 days prior to
             the first dose of IP.

          -  Have a diffuse HCC (Hepatocellular Carcinoma), vascular invasion or extrahepatic
             tumor.

          -  Main portal vein thrombosis present on imaging.

          -  History of hepatic encephalopathy within past 12 months or require medications to
             prevent or control encephalopathy.

          -  Ascites within 6 weeks prior to study treatment.

          -  Any contraindications for embolization.

          -  Has an active infection such as TB, HIV, hepatitis B or C.

          -  History of another primary malignancy.

          -  History of leptomeningeal carcinomatosis.

          -  History of active primary immunodeficiency.

          -  Any unresolved toxicities from previous anticancer therapy.

          -  Grade ≥2 neuropathy.

          -  History of bleeding disorder.

          -  History or current use of immunosuppressive medications within 14 days prior to study
             medications.

          -  Has an active known or suspected autoimmune disease.

          -  Patients with hypothyroidism.

          -  Any active skin conditions.

          -  History of allogenic organ transplantation.

          -  Significant heart disease.

          -  Patients weighing < 30 kg.

          -  Patients with celiac disease not controlled by diet alone.

          -  Patient with uncontrolled intercurrent illness including, but not limited to,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Have received a live vaccine within 30 days prior to study drug.

          -  Woman who are pregnant or breastfeeding.

          -  Known allergy or hypersensitivity to the study drug.

          -  Have received durvalumab, tremelimumab, anti-PD-1, anti-PD-L1 or anti-CTLA-4 in a
             prior study.

          -  Unwilling or unable to follow the study schedule for any reason.